top of page

YouTube 'Team up' with Big Pharma to Remove any Mention of Vaccine Deaths

The video streaming service says it will soon remove all content that argues Covid vaccines can cause serious side-effects and are unsafe for use. Matt Halprin, the Global Head of Trust and Safety at the Google-owned company, is alarmed by the presence of what he described as “vaccine misinformation” across the world. Youtube are to deny any deaths or life-changing events have been caused, or contributed to, by the jab even though evidence is reported by the Government on a weekly basis and dozens of coroner have confirmed the cause of death in their patients has been the Covid-19 vaccine.

The Guardian reported:

From Wednesday, the video streaming site, which has already banned Covid jab falsehoods, will take down content that claims any approved vaccine is dangerous and causes chronic health defects. Under previous guidelines, the platform demoted – effectively hiding from view – videos that spread misinformation about non-Covid vaccines or promoted vaccine hesitancy.

Last year, YouTube implemented a ban on Covid vaccine misinformation videos, which has led to 130,000 pieces of content being taken down since then. YouTube, which is owned by Google, has removed a total of 1m videos for spreading general Covid falsehoods since the pandemic broke out.

Matt Halprin… said vaccine misinformation was a global problem and had spilled over from the spreading of falsehoods about Covid jabs.

However, Vision News has discovered that Alphabet, Google's parent company, 'teamed up' with Novartis; Sanofi and Pfizer to run a clinical trials programme just weeks before the Pandemic started. The same big pharma now marketing their experimental drug to every person on earth and whose results Youtube are erasing from public view.

Verily, the health and life sciences company under Google parent-company Alphabet, is moving into the clinical trials space. - CNBC_2019

CNBC in the US ran a story in 2019 that, at the time, got little or no attention entitled: Google sister-company Verily is teaming with big pharma on clinical trials and documents how Verily (Google company) is 'moving into the clinical trial market.'

It goes on to state that: 'Pharma companies are looking to work with Verily, which is part of the Alphabet umbrella, as they try to find ways to modernize their clinical trials and speed up the time it takes to bring a new drug to market. Verily kicked off its own study, dubbed Baseline, in 2017. It learned a lot about clinical trials through that experience and is now expanding its efforts to include more participants and more industry partners.'

It continues: 'The company announced Tuesday strategic alliances with the pharmaceutical companies Novartis, Sanofi, Otsuka and Pfizer to help it move more deeply into the medical studies market. The goals for Verily, and its pharma partners, are to reach patients in new ways, make it easier to enroll and participate in trials, and aggregate data across a variety of sources, including the electronic medical record or health-tracking wearable devices.'

Clinical trials have historically been expensive processes that rely on outdated technologies. So pharma companies are looking to leverage the latest technologies from companies like Google to reach patients in a more targeted way and get their most promising drugs approved more quickly.

That’s where Verily comes in.

“Clinical trials haven’t changed much since the 1960′s,” acknowledged Rod MacKenzie, chief development officer at Pfizer. “We’ve been thinking about modernizing them for some time.”

“We see Verily’s technology as a way for us to reach patients and get them interested,” said Badhri Srinivasan, head of global development operations at Novartis. In an interview, Srinivasan shared an example of engaging people who are already searching on Google for relief from asthma symptoms. At that point, Verily could surface an ad to suggest they enroll in its clinical trial patient registry, dubbed Baseline, and sign up for relevant asthma-related clinical trials if they chose to do so.

YouTube and Google have far too much control over what we see, there control of the narrative has been immense with Silicon Valley acting like the Ministry of Truth from Orwell's dystopian classic. The fact that their parent company Alphabet has teamed-up with the likes of Pfizer to run clinical trials means their reason for removing any negative content about those trials frankly stinks to high heaven.

Related Article

YouTube Putting Lives at Risk With Covid Censorship Says Expert

Censorship of facts not only authoritarian but actively putting lives at risk An expert on media policy has said that Youtube's censorship on all things covid has put patient's lives at risk and may have added to the toll of vaccine deaths. The expert, who wants to remain anonymous due to his position in the industry, has told Vision News that the policy activated by YouTube and other social media giants may well have contributed to the death of thousands of people who were prevented from getting the full facts about vaccines. They went on to say: "Youtube are especially dangerous, they're actively censoring all Covid content. You are not allowed to say anything negative about any aspect of the Pandemic; you're not allowed to question the science, criticise the World Health Organisation or even criticise China's role in all this, and you're definitely not allowed to say anything about people dying from the vaccine, thats information they definitely don't want you sharing." "You're not even allowed to publish official government figures on deaths, you'll get that content removed, a ban and if you do it again, you'll be permanently suspended, and these are the actual figures from the government's yellow card system." "We've now seen over 1300 deaths as a direct result of vaccines in the UK alone, people should know this stuff, how can they make an informed decision on taking the vaccine if they don't know all the facts?" "People are dying, at a rate never seen before for a vaccine, and people have a right to know, but Youtube have worked hand in glove with governments controlling the information about them, even though they are still maintaining they are a content platform, not a content provider"

"I get people emailing me every day worried about being silenced, and many of them are doctors, scientists and pathologists." He goes on to say: "when all this is over and there is the inevitable class action from the families of the dead, will Facebook be prosecuted for withholding the facts about the vaccine? " The information, banned by Youtube is as follows: As of 9 June 2021, for the UK, 70,950 Yellow Cards have been reported for the Pfizer/BioNTech vaccine, 200,860 have been reported for the COVID-19 Vaccine AstraZeneca, 4,267 for the COVID-19 Vaccine Moderna and 790 have been reported where the brand of the vaccine was not specified. For the Pfizer/BioNTech vaccine, COVID-19 Vaccine AstraZeneca vaccines and COVID-19 Vaccine Moderna the overall reporting rate is around 3 to 7 Yellow Cards per 1,000 doses administered. In the week since the previous summary for 2 June 2021 we have received a further 2,952 Yellow Cards for the Pfizer/BioNTech vaccine, 5,219 for the COVID-19 Vaccine AstraZeneca, 989 for the COVID-19 Vaccine Moderna and 36 where the brand was not specified. Blood clots with concurrent low platelets The MHRA has undertaken a thorough review into UK reports of an extremely rare specific type of blood clot in the brain, known as cerebral venous sinus thrombosis (CVST) occurring together with low levels of platelets (thrombocytopenia) following vaccination with the COVID-19 Vaccine AstraZeneca. It is also considering other blood clotting cases (thromboembolic events) alongside low platelet levels. This ongoing scientific review has concluded that the evidence of a link with COVID-19 Vaccine AstraZeneca is stronger and an announcement was made on 7 April 2021 with a further statement on 7 May. We have continued to publish the latest breakdown of all cases of these extremely rare side effects on a weekly basis. In this report (page 13) we provide updated information on cases received up to 9 June 2021. Our advice remains unchanged. Anyone who experienced cerebral or other major blood clots occurring with low levels of platelets after their first vaccine dose of COVID-19 Vaccine AstraZeneca should not have their second dose. Anyone who did not have these side effects should come forward for their second dose when invited. The MHRA recently confirmed that the evidence to date does not suggest that the COVID-19 Vaccine AstraZeneca causes venous thromboembolism without a low platelet count. If you experience any of the following from around 4 days after vaccination should seek medical advice urgently:

  • a severe headache that is not relieved with simple painkillers or is getting worse or feels worse when you lie down or bend over

  • an unusual headache that may be accompanied by blurred vision, confusion, difficulty with speech, weakness, drowsiness or seizures (fits)

  • rash that looks like small bruises or bleeding under the skin beyond the injection site

  • shortness of breath, chest pain, leg swelling or persistent abdominal (tummy) pain.

Bell’s Palsy The MHRA continues to review cases reporting Bell’s Palsy and to analyse case reports against the number expected to occur by chance in the absence of vaccination (the ‘natural rate’). The number of reports of facial paralysis received so far is similar to the expected natural rate and does not currently suggest an increased risk following the vaccines. We will continue to monitor these events, including through evaluation of electronic healthcare record data. Thromboembolic events with concurrent low platelets Up to 9 June 2021, the MHRA had received Yellow Card reports of 390 cases of major thromboembolic events (blood clots) with concurrent thrombocytopenia (low platelet counts) in the UK following vaccination with COVID-19 Vaccine AstraZeneca. Twenty seven of these events have been reported after a second dose. Of the 390 reports, 207 occurred in women, and 180 occurred in men aged from 18 to 93 years. The overall case fatality rate was 18% with 71 deaths, four of which occurred after the second dose. Cerebral venous sinus thrombosis was reported in 140 cases (average age 46 years) and 250 had other major thromboembolic events (average age 54 years) with concurrent thrombocytopenia. The estimated number of first doses of COVID-19 Vaccine AstraZeneca administered in the UK by 9 June was 24.6 million and the estimated number of second doses was 17.7 million. The overall incidence after first or unknown doses was 14.8 per million doses. Taking into account the different numbers of patients vaccinated with COVID-19 Vaccine AstraZeneca in different age groups, the data shows that there is a higher reported incidence rate in the younger adult age groups following the first dose compared to the older groups (20.2 per million doses in those aged 18-49 years compared to 10.7 per million doses in those aged 50 years and over). The MHRA advises that this evidence should be taken into account when considering the use of the vaccine. There is now some evidence that the reported incidence rate is higher in females compared to men although this is not seen across all age groups and the difference remains small. The overall incidence after second doses was 1.5 per million doses. Taking into account the different numbers of patients vaccinated with COVID-19 Vaccine AstraZeneca in different age groups, the data shows that there is a lower reported incidence rate in younger adult age groups following the second dose compared to the older groups (0.7 per million doses in those aged 18-49 years compared to 1.5 per million doses in those aged 50 years and over). The number of second doses given to those in the 18-49 years age group is estimated to be 4 million while an estimated 13.7 million second doses have been given to patients aged 50+ years. These rates should not be directly compared to the incidence rates reported after the first dose as the time for follow-up and identification of cases after second doses is more limited and differs across age groups. However, the data are reassuring at this stage and suggest that the reported incidence rate following a second dose is smaller than that seen following a first dose. These reports have also been analysed by the Government’s independent advisory body, the COVID-19 Vaccines Benefit Risk Expert Working Group, which includes lay representatives and advice from leading haematologists. On the basis of this ongoing review, the advice remains that the benefits of the vaccine outweigh the risks in the majority of people. Menstrual disorders (period problems) and unexpected vaginal bleeding The MHRA is closely monitoring reports of menstrual disorders (period problems) and unexpected vaginal bleeding following vaccination against COVID-19 in the UK. These reports have also been reviewed by the independent experts of the Commission on Human Medicines’ COVID-19 Vaccines Benefit Risk Expert Working Group and members of the Medicines for Women’s Health Expert Advisory Group. The current evidence does not suggest an increased risk of either menstrual disorders or unexpected vaginal bleeding following the vaccines. A range of menstrual disorders have been reported after all three of the COVID-19 vaccines including heavier than usual periods, delayed periods and unexpected vaginal bleeding. The number of reports of menstrual disorders and vaginal bleeding is low in relation to both the number of females who have received COVID-19 vaccines to date and how common menstrual disorders are generally. The MHRA will continue to closely monitor reports of menstrual disorders and vaginal bleeding with COVID-19 vaccines. Myocarditis and Pericarditis (inflammation of the heart) The MHRA is closely monitoring cases of myocarditis- and pericarditis (inflammation of the heart) received with the COVID-19 vaccines. We have received 39 reports of myocarditis and 27 reports of pericarditis following use of the Pfizer/BioNTech vaccine, as well as one report each of viral pericarditis and Streptococcal endocarditis up to and including 2 June 2021. For the COVID-19 Vaccine AstraZeneca there have been 34 reports of myocarditis and 61 reports of pericarditis following vaccination up to and including 9 June 2021. There has been two reports of myocarditis and no reports of pericarditis following use of COVID-19 Vaccine Moderna up to the same date. These cases have been analysed against the number of cases expected to occur by chance in the absence of vaccination (the “background/natural rate”). The number of cases of myo- and pericarditis reported with the vaccines in the UK remains similar or below the expected background rate in different age groups within the general population and does not currently indicate an increased risk following vaccination against COVID-19. We will continue to closely monitor these events reported in the UK and internationally. It is important that anyone who experiences symptoms such as chest pain, shortness of breath or feelings of having a fast-beating, fluttering, or pounding heart urgently seeks medical attention. Events with a fatal outcome Vaccination and surveillance of large populations means that, by chance, some people will experience and report a new illness or events in the days and weeks after vaccination. A high proportion of people vaccinated early in the vaccination campaign were very elderly, and/or had pre-existing medical conditions. Older age and chronic underlying illnesses make it more likely that coincidental adverse events will occur, especially given the millions of people vaccinated. It is therefore important that we carefully review these reports to distinguish possible side effects from illness that would have occurred irrespective of vaccination. Fatal cases associated with extremely rare blood clots with lowered platelets are described above. Part of our continuous analysis includes an evaluation of natural death rates over time, to determine if any specific trends or patterns are occurring that might indicate a vaccine safety concern. Based on age-stratified all-cause mortality in England and Wales taken from the Office for National Statistics death registrations, several thousand deaths are expected to have occurred, naturally, within 7 days of the many millions of doses of vaccines administered so far, mostly in the elderly. The MHRA has received 421 UK reports of suspected ADRs to the Pfizer/BioNTech vaccine in which the patient died shortly after vaccination, 885 reports for the COVID-19 Vaccine AstraZeneca, 4 for the COVID-19 Vaccine Moderna and 22 where the brand of vaccine was unspecified. The majority of these reports were in elderly people or people with underlying illness. Usage of the COVID-19 Vaccine AstraZeneca has increased rapidly and as such, so has reporting of fatal events with a temporal association with vaccination however, this does not indicate a link between vaccination and the fatalities reported. Review of individual reports and patterns of reporting does not suggest the vaccine played a role in the death. A range of other isolated or series of reports of non-fatal, serious suspected ADRs have been reported. These all remain under continual review, including through analysis of expected rates in the absence of vaccine. There are currently no indications of specific patterns or rates of reporting that would suggest the vaccine has played a role. 1,322 Deaths 347,027 Adverse Events

55 views0 comments


bottom of page